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Introduction
Lycopene (C40H56), as a unsaturated red-pigmented lin-
ear carotenoid, has a molecular weight of 536.85 Da, and 
11 conjugated and 2 non-conjugated double bonds; it is 
lipophilic and therefore more soluble in organic solvents 
(1-3). Lycopene is a lipid-soluble antioxidant and has been 
inversely associated with lipid peroxidation, comprising 
low-density lipoprotein oxidation and reduced oxidative 
stress and inflammation. In addition, lycopene can be 
considered as the most predominant carotenoid in plasma 
of human (4). Moreover, it is a carotenoid that is naturally 
found in tomatoes which acts as an antioxidant (5) and a 
potential chemo-preventive agent (6) with a singlet-oxy-
gen and free radical scavenging capacity (7). A half-life of 
about 2–3 days can be considered for it when consumed. 
There is no official recommended amount for the daily 
intake of lycopene (8,9). Tomatoes could provide almost 
85% of the lycopene in the diet as well as watermelon, 
guava, pink grapefruit, and rosehip (10).
Lycopene is one of more than 600 carotenoids were found 
in the nature with a variety of biological activities such as 
aging prevention, cancer prevention, anti‐inflammation, 
and oxidative (11). It contains a high level of antioxidant 
to help preventing different kinds of oxidative damages in 
tissues and cells. Lycopene has indeed received special at-
tention due to the fact that it is a highly efficient antioxi-
dant as well as having the function of singlet‐oxygen and 
free radical scavenging (6,12,13). Thus, lycopene, as a bio-
active compound, may help prevention of chronic disease 
(14). Although lycopene is a potent antioxidant in vitro; 
however, its role in human health might be because of its 
bioactive metabolites. 
It has been suggested that many noncommunicable and 
chronic diseases, such as cardiovascular disease, cancer, 
diabetes and eye diseases are the result of long standing 
oxidative stress. Antioxidants such as vitamin E, lycopene 
and tocopherols, may have an important role to play in 
protection against oxidative damage. Lycopene, as an ef-
fective antioxidant and a free radical scavenger has been 
demonstrated by several studies. Research has suggested 
that lycopene could reduce lipid peroxidation and ath-
erogenesis in hemodialysis patients with chronic renal 
failure (15,16). In fact, increased production of oxidative 
stress markers and decreased concentrations of antioxi-
dants could define oxidative stress resulting from cisplatin 
(17,18). 
Lycopene and kidney
Several studies have investigated the potential protec-
tive effect of lycopene on many diseases such as impaired 
cardiac and renal function (19), cisplatin-induced neph-
rotoxicity and oxidative stress in rat (7), chronic kidney 
disease (CKD) (20), renal cell carcinoma (21,22), mercury 
kidney damage (23), oxidative stress and inflammation 
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in the kidney due to obesity (24), renal dysfunction and 
oxidative stress (25), development of diabetic nephropa-
thy and ameliorates renal function via improving oxida-
tive status through strong antioxidant properties and also 
lipid-lowering effect (26), cisplatin-induced nephrotoxic-
ity in rats (18,27), lipid peroxidation and atherogenesis 
in hemodialysis individual (16), DNA damage (28) and 
nephrotoxicity and oxidative stress (29) induced by och-
ratoxin A, colistin-induced nephrotoxicity in mice (30), 
contrast medium-induced oxidative stress, inflammation, 
autophagy, and apoptosis in rat kidney (31), kidney tissue 
diseases (32).
Lycopene is a potent antioxidant which could supply the 
protection against cellular damage due to reactive oxygen 
species (33,34). Antioxidant vitamins and dietary con-
stituents (such as, vitamin C, tocopherols, a-carotene and 
other carotenoids) could play a substantial role in protec-
tion against oxidative damage (35-37). In addition, while 
there is interest in the association of lycopene and some 
diseases such as cardiovascular disease, eye health and 
skin, the main part of research has focused on prostate 
cancer. Various epidemiological studies have detected that 
higher intakes of tomato and tomato product consump-
tion are associated with a reduced risk of prostate cancer 
(11,38,39). In addition, lycopene as a potent antioxidant, 
may contribute to the lessening of oxidative stress in met-
abolic diseases (40) as well as protection against oxidation 
of lipids, proteins and DNA (19).
Conclusion
Lycopene could be considered as the most effective anti-
oxidant among the carotenoids. It has been reported to be 
able to attenuate oxidative stress and exert its anticancer 
effects both in vitro and in vivo (33). Humans and ani-
mals could earn lycopene from different sources specially 
dietary sources, because they cannot synthesize it (41). 
Lycopene is shown to reduce the risk of some chronic dis-
eases including cancer (For example prostate cancer) and 
cardiovascular disorders. Lycopene and vitamin C have 
been shown to have an influence on the biomarkers of 
oxidative stress and inflammation. Low plasma levels of 
lycopene and analgesic consumption may increase more 
the risk of CKD. Lycopene not only can significantly de-
crease plasma total cholesterol, triglyceride and low den-
sity lipoprotein cholesterol levels and conversely increase 
high density lipoprotein cholesterol value (26). In fact, the 
favorable effects of lycopene is being as an anti-inflamma-
tory, anti-autophagic, and antiapoptotic substance (31).
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